Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aplidin PharmaMar.

Lei Yao1

  • 1Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Yaol@mail.nih.gov

Idrugs : the Investigational Drugs Journal
|June 6, 2003
PubMed
Summary
This summary is machine-generated.

Aplidin is a novel cell cycle inhibitor under development for treating multiple cancers. This includes non-Hodgkin's lymphoma and lung cancer, offering potential new therapeutic options.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cushing syndrome caused by an ectopic ACTH-producing pituitary adenoma of the clivus region: A rare case report and literature review.

Medicine·2023
Same author

Genome characterization based on the Spike-614 and NS8-84 loci of SARS-CoV-2 reveals two major possible onsets of the COVID-19 pandemic.

PloS one·2023
Same author

[Health Risk Assessment of Heavy Metals in Soil and Wheat Grain in the Typical Sewage Irrigated Area of Shandong Province].

Huan jing ke xue= Huanjing kexue·2023
Same author

A Temperature-to-Frequency Converter-Based On-Chip Temperature Sensor with an Inaccuracy of +0.65 °C/-0.49 °C.

Sensors (Basel, Switzerland)·2023
Same author

Dual-asymmetrically selective interfaces-enhanced poly(lactic acid)-based nanofabric with sweat management and switchable radiative cooling and thermal insulation.

Journal of colloid and interface science·2023
Same author

Recent advances in the development of Rho kinase inhibitors (2015-2021).

Medicinal research reviews·2023
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Aplidin is an investigational drug developed by PharmaMar SA.
  • It functions as a cell cycle inhibitor.

Purpose of the Study:

  • To evaluate the potential of Aplidin as a cancer therapeutic.
  • To identify specific cancer types for which Aplidin may be effective.

Main Methods:

  • Preclinical studies and/or clinical trials investigating Aplidin's efficacy.
  • Mechanism of action studies focusing on cell cycle inhibition.

Main Results:

  • Aplidin demonstrates potential in preclinical models or early clinical studies.
  • The drug's activity is linked to its ability to inhibit cancer cell proliferation.

Conclusions:

  • Aplidin shows promise as a treatment for various malignancies.
  • Further research is warranted to establish its therapeutic role in specific cancers.